Rakovina Therapeutics Unveils New Data on ATR Inhibitors
VANCOUVER, British Columbia – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV, FSE: 7JO0), a pioneering biopharmaceutical firm dedicated to advancing cancer treatments through AI-enhanced drug discovery, is excited to announce that it will present new preclinical data derived from its innovative ATR inhibitor program at a significant upcoming international conference.
Importance of ATR Inhibitors in Cancer Treatment
DNA damage repair (DDR) enzymes play a critical role in maintaining cellular stability. Among these, Ataxia Telangiectasia and Rad3-related protein serine/threonine kinase (ATR) has emerged as a promising target due to its involvement in various cancer therapies. While inhibiting DDR enzymes presents a viable therapeutic avenue for treating various cancers, a significant challenge remains: these compounds often struggle to effectively cross the blood-brain barrier, limiting their use in treating brain tumors and metastases.
Highlighting Collaborative Innovation
At the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled to take place at the Hynes Convention Center, Rakovina will showcase its breakthroughs in ATR inhibition, developed in partnership with Variational AI. Utilizing the advanced Enki™ generative AI platform, this collaboration has led to the creation of a shortlist of compounds specifically designed for targeting ATR. Through rigorous in vitro and in vivo studies, Rakovina has identified a selection of compounds that demonstrate promising potency, selectivity, and the ability to penetrate the central nervous system.
Insights from Leadership
“We are thrilled to present our findings at this prestigious conference,” said Prof. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics. “The advancements revealed in our data underscore the efficacy of our ATR inhibitor drug candidates in crossing the blood-brain barrier—a crucial milestone in addressing the unmet needs in current cancer therapies.”
Presentation Session Details
The presentation will take place during a poster session on October 25, where Rakovina will share:
- Title: Novel ATR inhibitors with CNS penetrance developed by artificial intelligence
- Time: Poster session C, Saturday, October 25, 12:30 – 4 PM ET
Conference Overview
The AACR-NCI-EORTC International Conference convenes leading experts in cancer research, attracting a diverse group of academics, investors, and industry representatives from around the world. This esteemed event provides a platform for discussing groundbreaking innovations in drug development and molecular biology. Attendees will benefit from insights into early-phase clinical trials and emerging therapeutic strategies that are shaping the future of cancer treatments.
About Rakovina Therapeutics Inc.
Rakovina Therapeutics is committed to the development of novel cancer therapies using cutting-edge technologies focused on the DNA damage response. With an emphasis on artificial intelligence through proprietary platforms like Deep-Docking™ and Enki™, the company accelerates the optimization and development of drug candidates.
The company’s pipeline is rich with unique DNA damage response inhibitors, with aspirations to progress promising candidates into clinical trials, tapping into collaborative opportunities with pharmaceutical partners.
For more details and updates about Rakovina Therapeutics, visit www.rakovinatherapeutics.com.
Frequently Asked Questions
What are ATR inhibitors and why are they important?
ATR inhibitors target the DNA damage response, offering a therapeutic strategy for various cancers, especially important for conditions that affect the central nervous system.
When and where will Rakovina present their findings?
Rakovina Therapeutics will present their findings at the AACR-NCI-EORTC International Conference on October 25 during a poster session.
How does AI contribute to Rakovina's drug discovery process?
AI assists in optimizing drug candidates more rapidly by analyzing and predicting molecular interactions and properties, enhancing the discovery of effective therapies.
What is the significance of crossing the blood-brain barrier?
Crossing the blood-brain barrier allows therapies to target brain tumors effectively, addressing a significant challenge in treating central nervous system cancers.
How can I contact Rakovina Therapeutics for more information?
For inquiries, you can reach out to Michelle Seltenrich at IR@rakovinatherapeutics.com or call 778-773-5432.
